← Back to Clinical Trials
Recruiting NCT07293429

NCT07293429 Combined Posture Correction and Resistive Respiratory Muscles Training in COPD With FHP

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07293429
Status Recruiting
Phase
Sponsor Riphah International University
Condition COPD - Chronic Obstructive Pulmonary Disease
Study Type INTERVENTIONAL
Enrollment 72 participants
Start Date 2025-12-02
Primary Completion 2026-02-25

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Resistive inspiratory muscles trainingResistive expiratory muscles training:Combined resistive inspiratory and expiratory muscles training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 72 participants in total. It began in 2025-12-02 with a primary completion date of 2026-02-25.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and airflow limitation, often exacerbated by postural abnormalities such as forward head posture (FHP). FHP can lead to significant alterations in breathing patterns, reducing the efficiency of respiratory muscles and impairing lung function. Patients with COPD and FHP frequently exhibit muscular imbalances, where overactive accessory muscles compensate for weakened primary respiratory muscles Resistive Inspiratory Muscle Training strengthens inhalation muscles using resistance devices to enhance respiratory function in COPD patients. Resistive Expiratory Muscle Training focuses on strengthening exhalation muscles through resistance during exhalation, improving breathing efficiency. Posture Correction Exercises address forward head posture by stretching tight muscles and strengthening weak ones to optimize breathing mechanics. Combined Resistive Inspiratory and Expiratory Muscle Training integrates both inspiratory and expiratory muscle training, using resistance for both inhalation and exhalation, to maximize respiratory efficiency and overall lung function in COPD patients. The objective of the study is to determine the effects of combined exercise and resistive respiratory muscles training on dyspnea, chest expansion, craniovertebral angle and pulmonary function test, in COPD patients with forward head posture. Patients of COPD with forward head posture will be recruited by convenient sampling technique using seal opaque method. 72 patients will be equally divided into three groups with 24 patients each. Posture correction exercises will be added as baseline treatment for all three groups session. GROUP A will be treated with resistive inspiratory muscles training (RIMT). GROUP B will be treated with resistive expiratory muscles training (REMT). GROUP C will be treated with combined resistive inspiratory and expiratory muscles technique (RIMT+REMT).treatment session will be of 8 weeks and will include three reading (pre, post treatment and one follow-up). Outcomes measurement will include; dyspnea by dyspnea 12 questionnaires, chest expansion by measuring tape, craniovertebral angle by radiograph and pulmonary function test by spirometer. Data will be analyzed by SPSS software version 21.

Eligibility Criteria

Inclusion Criteria: * • Patients of COPD at stage 1 and 2 * COPD with forward head posture. * Craniovertebral angle \< 53 degrees (20) * Age 40-60 * Both genders * Spirometric evidence of significant chronic air-flow limitation (ie, FEV1 of 50% of predicted and FEV1/FVC ratio of 70% of predicted) in whom COPD had been diagnosed (21) * Persistent dyspnea with a self-rated intensity of ⩾6 (out of 10) on a visual analogue * Having muscular tightness (pectoralis major and minor, upper trapezius, sternocleidomastoid) Exclusion Criteria: * • COPD with severe complications (respiratory infections, acute exacerbations, pulmonary hypertension) * COPD with cardiovascular complications (Cor Pulmonale, atherosclerosis, risk of venous thromboembolism) * Unstable respiratory, neurological, and cardiovascular conditions * Congenital Cervical/spinal deformity * Patients with frozen shoulder, shoulder, cervical radiculopathy) * Uncontrolled underlying conditions(22)

Contact & Investigator

Central Contact

Imran amjad, Phd

✉ imran.amjab@riphah.edu.pk

📞 03324390125

Principal Investigator

wajeeha zia, PP-DPT

PRINCIPAL INVESTIGATOR

Riphah International University

Frequently Asked Questions

Who can join the NCT07293429 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, up to 60 Years, studying COPD - Chronic Obstructive Pulmonary Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07293429 currently recruiting?

Yes, NCT07293429 is actively recruiting participants. Contact the research team at imran.amjab@riphah.edu.pk for enrollment information.

Where is the NCT07293429 trial being conducted?

This trial is being conducted at Lahore, Pakistan.

Who is sponsoring the NCT07293429 clinical trial?

NCT07293429 is sponsored by Riphah International University. The principal investigator is wajeeha zia, PP-DPT at Riphah International University. The trial plans to enroll 72 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology